Transition from BOS to RAS Impairs Prognosis After Lung Transplantation-CLAD Subtype Analysis by CT Volumetry

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Oct 12

PMID 36223371

Authors

Laura Perakyla

Antti Nykanen

Anneli Piilonen

Risto Kesavuori

Maija Halme

Peter Raivio

Affiliations

Soon will be listed here.

Abstract

Background: Chronic lung allograft dysfunction (CLAD), subclassified into bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS), limits survival after lung transplantation. Information concerning transition from BOS to RAS is limited. We aimed to characterize the lung volume change after BOS diagnosis by computed tomography (CT) volumetry and to determine the incidence, risk factors and clinical significance of BOS to RAS transition.

Methods: CT volumetry measurements were performed from 63 patients with CLAD initially classified as BOS by CT volumetry. BOS patients with lung volume remaining >85% of baseline were classified as persistent BOS, whereas BOS patients whose lung volume permanently decreased to ≤85% of baseline were classified as BOS to RAS transition.

Results: During follow-up (median 9.8 years) eight patients (12.7%) were classified as BOS to RAS transition, which decreased recipient (p = 0.004) and graft survival (p = 0.020) in comparison to patients with persistent BOS. Opacities on chest imaging preceded BOS to RAS transition in 88% of patients. Opacities on chest imaging at BOS diagnosis and early CLAD diagnosis after transplantation were risk factors for transition.

Conclusion: Based on lung volume decrease measured by CT volumetry, a small proportion of BOS patients transitioned to RAS which had an adverse effect on recipient and graft survival.

Citing Articles

Time to Rethink Bronchiolitis Obliterans Syndrome Following Lung or Hematopoietic Cell Transplantation in Pediatric Patients.

Jaing T, Wang Y, Chiu C Cancers (Basel). 2024; 16(21).

PMID: 39518153 PMC: 11545638. DOI: 10.3390/cancers16213715.

Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.

Bery A, Belousova N, Hachem R, Roux A, Kreisel D Transplantation. 2024; 109(3):454-466.

PMID: 39104003 PMC: 11799353. DOI: 10.1097/TP.0000000000005162.

References

Garfield J, Marchetti N, Gaughan J, Steiner R, Criner G . Total lung capacity by plethysmography and high-resolution computed tomography in COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:119-26. PMC: 3292389. DOI: 10.2147/COPD.S26419. View

Verleden S, Ruttens D, Vandermeulen E, Vaneylen A, Dupont L, Van Raemdonck D . Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?. Transplantation. 2013; 95(9):1167-72. DOI: 10.1097/TP.0b013e318286e076. View

Sato M, Waddell T, Wagnetz U, Roberts H, Hwang D, Haroon A . Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011; 30(7):735-42. DOI: 10.1016/j.healun.2011.01.712. View

Horie M, Levy L, Houbois C, Salazar P, Saito T, Pakkal M . Lung Density Analysis Using Quantitative Chest CT for Early Prediction of Chronic Lung Allograft Dysfunction. Transplantation. 2019; 103(12):2645-2653. DOI: 10.1097/TP.0000000000002771. View

Byrne D, Nador R, English J, Yee J, Levy R, Bergeron C . Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings. Radiol Cardiothorac Imaging. 2021; 3(1):e200314. PMC: 7978021. DOI: 10.1148/ryct.2021200314. View

Van Herck A, Verleden S, Sacreas A, Heigl T, Vanaudenaerde B, Dupont L . Validation of a post-transplant chronic lung allograft dysfunction classification system. J Heart Lung Transplant. 2018; 38(2):166-173. DOI: 10.1016/j.healun.2018.09.020. View

Glanville A, Verleden G, Todd J, Benden C, Calabrese F, Gottlieb J . Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019; 38(5):483-492. DOI: 10.1016/j.healun.2019.03.008. View

Verleden S, Vos R, Vanaudenaerde B, Verleden G . Chronic lung allograft dysfunction phenotypes and treatment. J Thorac Dis. 2017; 9(8):2650-2659. PMC: 5594185. DOI: 10.21037/jtd.2017.07.81. View

Fuchs E, Levy L, Huszti E, Renaud-Picard B, Berra G, Kawashima M . Significance of phenotype change after chronic lung allograft dysfunction onset. Transpl Int. 2021; 34(12):2620-2632. DOI: 10.1111/tri.14157. View

10.

Yusen R, Edwards L, Kucheryavaya A, Benden C, Dipchand A, Dobbels F . The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014; 33(10):1009-24. DOI: 10.1016/j.healun.2014.08.004. View

11.

Perakyla L, Raivio P, Kesavuori R, Piilonen A, Stark C, Halme M . Chronic lung allograft dysfunction subtype analysis by computed tomography volumetry. Clin Transplant. 2021; 36(1):e14507. DOI: 10.1111/ctr.14507. View

12.

Royer P, Olivera-Botello G, Koutsokera A, Aubert J, Bernasconi E, Tissot A . Chronic Lung Allograft Dysfunction: A Systematic Review of Mechanisms. Transplantation. 2016; 100(9):1803-14. DOI: 10.1097/TP.0000000000001215. View

13.

Nykanen A, Raivio P, Perakyla L, Stark C, Huuskonen A, Lemstrom K . Incidence and impact of chronic lung allograft dysfunction after lung transplantation - single-center 14-year experience. Scand Cardiovasc J. 2020; 54(3):192-199. DOI: 10.1080/14017431.2020.1726444. View

14.

Verleden G, Glanville A, Lease E, Fisher A, Calabrese F, Corris P . Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019; 38(5):493-503. DOI: 10.1016/j.healun.2019.03.009. View

15.

Verleden S, Von Der Thusen J, Van Herck A, Weynand B, Verbeken E, Verschakelen J . Identification and characterization of chronic lung allograft dysfunction patients with mixed phenotype: A single-center study. Clin Transplant. 2020; 34(2):e13781. DOI: 10.1111/ctr.13781. View

16.

Verleden S, Ruttens D, Vandermeulen E, Bellon H, Dubbeldam A, De Wever W . Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2016; 35(9):1078-84. DOI: 10.1016/j.healun.2016.03.022. View

17.

Saito T, Horie M, Sato M, Nakajima D, Shoushtarizadeh H, Binnie M . Low-dose computed tomography volumetry for subtyping chronic lung allograft dysfunction. J Heart Lung Transplant. 2015; 35(1):59-66. DOI: 10.1016/j.healun.2015.07.005. View

18.

Levy L, Huszti E, Renaud-Picard B, Berra G, Kawashima M, Takahagi A . Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system. J Heart Lung Transplant. 2020; 39(8):761-770. DOI: 10.1016/j.healun.2020.04.012. View

19.

Tissot A, Danger R, Claustre J, Magnan A, Brouard S . Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers. Front Immunol. 2019; 10:1681. PMC: 6650588. DOI: 10.3389/fimmu.2019.01681. View